摘要
Abstract
Objective:To investigate the clinical efficacy of nebulized recombinant human interferon α1b combined with acetylcysteine in children with bronchopneumonia.Methods:A retrospective study was conducted on 100 children with bronchopneumonia admitted to our hospital from December 2022 to December 2024.They were divided into a control group[treated with N acetylcysteine(NAC)aerosol inhalation]and a study group(treated with recombinant human interferon α1b in addition to the NAC regimen)based on different treatment methods,with 50 cases in each group.The following parameters were compared between the two groups:C reactive protein(CRP)and fractional exhaled nitric oxide(FeNO)levels;immune function indicators,including immunoglobulin M(IgM),immunoglobulin A(IgA),and immunoglobulin G(IgG)levels;pulmonary function parameters,including the ratio of time to peak tidal expiratory flow to total expiratory time(TPTEF/TE),tidal volume per kilogram of body weight(VT/kg),and the ratio of inspiratory to expiratory ratio(I/E);length of hospital stay and time to disappearance of clinical symptoms;as well as differences in clinical efficacy and adverse reactions.Results:After treatment,CRP and FeNO levels decreased in both groups,with the study group showing significantly lower values than the control group(P<0.05);both groups showed increases in TPTEF/TE,VT/kg,I/E,IgM,IgA,and IgG levels,with the study group having significantly higher values than the control group(P<0.05).The hospital stay and time to resolution of clinical symptoms in the study group were shorter than those in the control group(P<0.05);the total clinical efficacy rate in the study group(96.00%)was higher than that in the control group(82.00%,P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant human interferon α1b combined with NAC aerosol inhalation shows good therapeutic efficacy,can shorten the time to resolution of symptoms such as fever and cough,alleviate inflammatory responses,improve pulmonary function,and immune function,and does not increase the risk of adverse reactions.关键词
重组人干扰素α1b/乙酰半胱氨酸/支气管肺炎/疗效/肺功能Key words
recombinant human interferon α1b/acetylcysteine/bronchopneumonia/efficacy/pulmonary function分类
医药卫生
